Announcement • Dec 13
Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes Psycheceutical Bioscience, Inc. announce the appointment of Dr. Neilank K. Jha as its Chief Executive Officer. Dr. Jha is recognized for his extensive experience and wealth of knowledge in medicine, research and development, mergers and acquisitions, and restructuring. Most importantly, he brings an innovative vision to help the Company as it seeks to pioneer advancements in the field of neuroscience and Brain-Computer Interface technologies.Chad Harman, who has successfully led the Company as CEO, will be transitioning to the role of Chief Operating Officer, focusing on the critical operational aspects and strategic goals of the Company. Dr. Jha's multidisciplinary background makes him uniquely positioned to leverage Psycheceutical Bioscience's existing expertise in biotechnology and neuroscience and merge it with next-generation technology to expand into the BCI space. With this evolution, the Company will continue to focus on leading advancements in neuroscience and creating opportunities for groundbreaking research and development in BCI technologies. Dr. Jha pursued his undergraduate degree at the University of Toronto, medical school and a six-year neurosurgery residency at McMaster University, a two-year fellowship in complex spine at the University of Toronto, his MBA at Ivey Business School, and his Master's Degree in Behavioral Economics and Cognitive Psychology at the London School of Economics. He has inspired a generation of young business and medical colleagues to pursue developing novel therapeutics targeting the deep brain in order to improve care for conditions that have had limited treatment options. Dr. Jha also has a network that extends beyond North America to Asia, the Middle East, and Europe, uniquely positioning him to collaborate and work closely in different countries. Announcement • Dec 12
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman Psycheceutical Bioscience, Inc. announced the appointment of Dr. Neilank K. Jha as its new Executive Chairman. Dr. Jha is recognized for his extensive experience and wealth of knowledge in medicine, research and development, mergers and acquisitions, and restructuring. Most importantly, he brings an innovative vision to help the Company as it seeks to pioneer advancements in the field of neuroscience and Brain-Computer Interface (BCI) technologies. Chad Harman, who has successfully led the Company as CEO, will be transitioning to the role of Chief Operating Officer, focusing on the critical operational aspects and strategic goals of the Company. Harman will also be taking on the title of President of the Company's wholly-owned subsidiary Psycheceutical, Inc., with a focus on developing novel technologies for the delivery of safe, effective and non-hallucinogenic psychedelic medicines for mental health treatments. Dr. Jha's multidisciplinary background makes him uniquely positioned to leverage Psycheceutical Bioscience's existing expertise in biotechnology and neuroscience and merge it with next-generation technology to expand into the BCI space. With this evolution, the Company will continue to focus on leading advancements in neuroscience and creating opportunities for groundbreaking research and development in BCI technologies. Dr. Jha pursued his undergraduate degree at the University of Toronto, medical school and a six-year neurosurgery residency at McMaster University, a two-year fellowship in complex spine at the University of Toronto, his MBA at Ivey Business School, and his Master's Degree in Behavioral Economics and Cognitive Psychology at the London School of Economics. He has inspired a generation of young business and medical colleagues to pursue developing novel therapeutics targeting the deep brain in order to improve care for conditions that have had limited treatment options. Dr. Jha also has a network that extends beyond North America to Asia, the Middle East, and Europe, uniquely positioning him to collaborate and work closely in different countries. Announcement • Sep 27
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding Blue Water Ventures International, Inc. announced a private placement of a minimum of 454546 commo stock at a price of $0.12 for the gross proceeds of minimum of $50,000.06 and a maximum of $5,000,000 on September 26, 2023. The transaction is expected to close on April 29, 2024. The oversubscriptions will be accepted in the offering. The company will issue securities pursuant to exemption provided under Regulation C. 
